Shattuck Labs Announces Participation in Upcoming November Conferences
November 03 2022 - 7:30AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease, today
announced that company management will participate in three
investor conferences in November 2022.
Presentation Details
Conference: Cowen’s 6th Annual IO Next SummitFormat:
Fireside chat with covering analyst Marc Frahm, Ph.D.Presenter: Dr.
Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive
OfficerDate: November 11, 2022Time: 11:40 a.m. ET
Conference: 5th Annual Evercore ISI HealthCONx ConferenceFormat:
Fireside chat with covering analyst Jonathan Miller,
Ph.D.Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief
Executive OfficerDate: November 29, 2022Time: 1:00 p.m. ET
Conference: 34th Annual Piper Sandler Healthcare
ConferenceFormat: Corporate PresentationPresenter: Andrew Neill,
M.B.A., Shattuck’s Chief Financial OfficerDate: December 1,
2022Time: 11:10 a.m. ET
A live webcast of the fireside chats and presentation will be
available on the Events & Presentations section of
the Company’s website. A replay of the webcast will be archived for
up to 90 days following the presentation date.
About Shattuck Labs, Inc.Shattuck Labs, Inc.
(NASDAQ: STTK) is a clinical-stage biotechnology company pioneering
the development of bi-functional fusion proteins as a new class of
biologic medicine for the treatment of patients with cancer and
autoimmune disease. Compounds derived from Shattuck’s proprietary
Agonist Redirected Checkpoint, ARC®, platform simultaneously
inhibit checkpoint molecules and activate costimulatory molecules
with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L)
program, which is designed to block the CD47 immune checkpoint and
simultaneously agonize the CD40 pathway, is being evaluated in
multiple Phase 1 trials. A second product candidate, SL-279252
(PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid
tumors or lymphomas. Additionally, the company is advancing a
proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is
designed to bridge gamma delta T cells to tumor antigens for the
treatment of patients with cancer. Shattuck has offices in both
Austin, Texas and Durham, North Carolina. For more information,
please visit: www.ShattuckLabs.com.
Investor Contact:Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024